Eight Years of Experience on a DSMB for HIV/AIDS Trials
Unsolved Puzzles of HIV Pathogenesis
VIRAL RESPONSE DRIVEN ANTIRETROVIRAL THERAPY
IMMUNOLOGICAL MARKERS OF TREATMENT EFFICACY
CHANGES IN HIV-1 RNA LEVELS MEASURED BY QUANTITATIVE PCR DURING TREATMENT WITH 3TC TM MONOTHERAPY
LONGTERM AZT THERAPY DOES NOT ALTER LYMPHOCYTE FUNCTION IN ASYMPTOMATIC HIV INFECTION
CHARACTERIZATION OF RAPID AND SLOW PROGRESSORS IN A COHORT OF HIV-INFECTED INDIVIDUALS IN MADRID
DISTINCT CHANGES IN HIV-1 RNA VERSUS P24 IN SERUM DURING SHORT-TERM ZIDOVUDINE THERAPY IN ASYMPTOMATIC INDIVIDUALS WITH AND WITHOUT PROGRESSION TO AIDS
WHICH ANTIVIRAL AND WHEN?
HIV DRUG RESISTANCE
CD4 RISES DURING ANTI-HIV TREATMENT
TRANSMISSION OF 215 MUTANTS IN PRIMARY HIV INFECTION AND ANALYSIS AFTER 6 MONTHS OF ZIDOVUDINE
THE INFLUENCE OF COMBINATION THERAPY ON HIV-1 VIRAL LOAD AND DRUG RESISTANCE
THE PREDICTION OF CLINICAL EFFECT AND RATE OF RESISTANCE DEVELOPMENT FROM CELL CULTURE AND ANIMAL EXPERIMENTS WITH ANTI-HIV DRUGS
SEXUAL TRANSMISSION OF ZIDOVUDINE RESISTANT HIV-1
MECHANISTIC STUDIES OF NUCLEOSIDE RESISTANCE INVOLVING RECOMBINANT PURIFIED HIV REVERSE TRANSCRIPTASE
AZT RESISTANCE AND DISEASE PROGRESSION IN THE CONCORDE TRIAL
QUANTIFICATION OF SERUM VIRAL LOAD, RESISTANT MUTATIONS AND CLINICAL OUTCOME IN PATIENTS (MRC ALPHA TRIAL) STOPPING ZIDOVUDINE (ZDV) AND COMMENCING DIDANOSINE (ddI)
Characterisation of HIV drug sensitivity during antiretroviral treatment with a protease inhibitor (Ro 31–8959 - saquinavir) alone or in combination with zidovudine
Presentation withdrawn
EFFICACY AND TOXICITIES OF COMBINATION ANTIRETROVIRAL THERAPIES
Results of a randomized multicenter study (ISS 902) for the comparative evaluation of AZT and DDI in previously untreated patients with mildly symptomatic HIV disease
SURVIVAL IN ZDV-EXPERIENCED PATIENTS
COMBINATION 3TC (LAMIVUDINE) ZDV (ZIDOVUDINE) VS ZDV MONOTHERAPY IN ZDV NAIVE IIIV-1 POSITIVE PATIENTS WITH CEM OF 100–100 CELLS/MM
COMBINATION 3TC (LAMIVUDINE) ZDV (ZIDOVUDINE) VS ZDV MONOTHERAPY IN ZDV PRE-TREATED HIV-1 POSITIVE PATTENTS WITH CD4 OF 100–400 CELLSMM
Clinical Research, Prophylaxis, Therapy, and Care for HIV Disease in Resource-Poor Countries
CLINICAL TRIALS AND DEVELOPING COUNTRIES
TRAINING FOR CLINICAL MANAGEMENT IN RESOURCE POOR SETTINGS
VIRUCIDAL AGENTS AGAINST HIV TRANSMISSION
INTRACELLULAR PHOSPHORYLATION OF NUCLEOSIDE ANALOGUES IN VITRO AND IN VIVO
The pathogenesis and treatment of HIV-related thrombocytopenia
EFFICACY AND SAFETY OF STEALTH LIPOSOMAL DOXORUBICIN (DOX-SL(tm)) IN AIDS-RELATED KAPOSI'S SARCOMA
407 PATIENTS (PTS) WITH AIDS-RELATED NON-HODGKIN'S LYMPHOMA (AIDS-NHL)
EPIDEMIOLOGICAL, V1ROLOGICAL AND CLINICO-PATHOLOGICAL DATA FROM 114 PATIENTS (PTS) WITH HODGKIN'S DISEASE AND HIV INFECTION (HD-HIV)
HEW ANTI-VIRALS
SAFETY, PHARMACOKINETICS AND VIROLOGICAL/IMMUNOLOGICAL EFFICACY OF ABT-538, A HIV-PROTEASE INHIBITOR. A RANDOMISED, PLACEBO-CONTROLLED PHASE I/II STUDY
LONG TERM FOLLOW UP OF THE PHASE I/II STUDY OF SAQUINAVIR. IN ASYMPTOMATIC OR MILDLY SYMPTOMATIC HIV INFECTION
A PILOT STUDY OF THE SAFETY, TOLERANCE, PHARMACOKINETICS AND PHARMACODYNAMICS OF U-8720IE IN HIV INFECTED PERSONS
CLINICAL DEVELOPMENT OF HIV-1 RESISTANCE TO THE VIRAL PROTEASE INHIBITOR L-735, 524
PATHOGENESIS AND AETIOLOGY OF KAPOSI SARCOMA
THE TREATMENT OF KAPOSI'S SARCOMA WITH CYTOTOXIC AGENTS
Inhibition of angiogenesis as a potential therapeutic strategy for the treatment of AIDS-associated Kaposi's sarcoma (KS)
LIPOSOMAL ANTHRACYCLINE THERAPY OF KAPOSI'S SARCOMA (KS). OVERVIEW OF PILOT AND MULTICENTER PHASE 2 TRIALS
THE ROLE OF CYTOKINES AND CYTOKINE INHIBITORS IN AIDS-RELATED KAPOSI'S SARCOMA
KAPOSI'S SARCOMA
THE MANAGEMENT OF INFECTIONS IN CHILDREN
THE PREVENTION OF VERTICAL TRANSMISSION
CLINICAL TRIAL ISSUES IN CHILDREN
PROPHYLACTIC VACCINES FOR HIV
THERAPEUTIC VACCINS
CHANGING T-CELL IMMUNITY IN HIV VACCINATION
A PILOT PHASE II STUDY OF THE TOLERANCE AND SAFETY OF HIV pl7/p24
CYTOKINE THERAPIES FOR HIV
PHASE I A/B TRIAL OF IMIQUIMOD, AN ORAL INTERFERON INDUCER IN ASYMPTOMATIC HTV POSITIVE INDIVIDUALS
The treatment and proplylaxis of opportunistic infections
THE EFFECT OF ACYCLOVIR COTHERAPY ON SURVIVAL IN ADVANCED HIV DISEASE
TREATMENT AND PREVENTION OF TOXOPLASMIC ENCEPHALITIS
TREATMENT AND SUPPRESSION OF CMV INFECTIONS IN HIV-INFECTED PATIENTS
RESULTS FROM RECENT THERAPEUTIC TRIALS FOR OPPORTUNISTIC INFECTIONS (Ols) FROM THE UNITED STATES
Tuberculosis and HIV in New York City
FLUCONAZOLE RESISTANCE IN CANDIDA ALBICANS. CORRRELATION BETWEEN CLINICAL AND IN VITRO DATA IN PATIENTS WITH AIDS
AZOLE REFRACTORY ORAL CANDIDIASIS - CLINICAL AND MYCOLOGICAL FEATURES
IMMUNOGENICITY OF BACTERIAL POLYSACCHARIDES IN CHILDREN WITH HIV INFECTION
NONTUBERCULOUS MYCOBACTERIAL INFECTIONS IN HIV DISEASE
TREATMENT OF GUT INFECTION
CHAGAS' DISEASE IN HIV INFECTION
A PROSPECTIVE STUDY OF INFECTION BY MYCOBACTERIUM AVIUM/ INTRACELLULARE(MAC) IN IMMUNODEFICIENT HIV POSITIVE PATIENTS
OUTCOMES AND COSTS OF SHORT- AND LONGTERM RIFABUTIN PROPHYLAXIS FOR MYCOBACTERIUM AVIUM (MAC) DISEASE IN AIDS PATIENTS IN THE UNITED KINGDOM
UVEITIS AND RIFABUTIN
RESISTANCE TO SAQUINAVIR (Ro 31–8959) OCCURS DURING PATIENT TREATMENT
LONG TERM FOLLOW-UP OF PATIENTS TREATED WITH DDI
THE APPEARANCE OF DRUG RESISTANCE ASSOCIATED POINT MUTATIONS IN HIV-1 PLASMA RNA PRECEDES THEIR APPEARANCE IN PROVIRAL DNA
A METHOD FOR QUANTIFICATION OF GENOTYPIC DRUG RESISTANCE IN CLINICAL SAMPLES
GENOTYPIC CHARACTERISATION OF HIV-1 FROM PATIENTS AFTER PROLONGED TREATMENT WITH THE PROTEINASE INHIBITOR SAQUINAVIR
HIV-I Mutation to Escape the Effect of Protease-Inhibitors in vitro Impaired its Infectivity and Cytopathogenicity
A PLACEBO CONTROLLED TRIAL OF AZT ALONE OR IN COMBINATION WITH DDI OR DDC
ANTIVIRAL POTENCY OF AZT + 3TC COMBINATION THERAPY IN VIVO SUPPORTS IN VITRO VIROLOGICAL OBSERVATIONS
UNCHANGED PHARMACOKINETICS OF AZIDOTHYMIDIN (AZT) IN HIV-INFECTED HEMOPHILIACS WITH CONCOMITANT CHRONIC HEPATITIS
VALIDATION OF ALKALINE PHOSPHATASE ( AP) USED TO QUANTIFY INTRACELLULAR ( IC ) ZIDOVUDINE ( ZDV ) METABOLITES
PHARMACOKINETIC EVALUATION OF DRUG INTERACTIONS BETWEEN FLUCONAZOLE AND ZIDOVUDINE IN HIV-INFECTED PATIENTS
Measurement of the anti HIV agent 2',3'-didehydro-2'3' dideoxythymidine (d4T) by competitive ELISA
DRUG INTERACTIONS WITH ZIDOVUDINE PHOSPHORYLATION IN VITRO
ZIDOVUDINE PHOSPHORYLATION IN HIV PATIENTS AND SERONEGATIVE VOLUNTEERS
PHAEMACOKINETICS OF ZIDOVUDINE AND DIDEOXYINOSINE ALONE AND IN COMBINATION IN CHILDREN WITH HIV INFECTION
THE PHARMACOKINETICS OF FLUCONAZOLE AFTER A SINGLE INTRAVENOUS DOSE IN AIDS PATIENTS
TREATMENT OF AIDS-RELATED SYSTEMIC MYCOSES WITH A LIPID EMULSION FORMULATION OF AMPHOTERICIN B
ADVERSE DRUG REACTIONS IN HIV POSITIVE PATIENTS. AN IRISH PERSPECTIVE
ANTIPROTOZOAL PROPHYLAXIS WITH DAPSONE AND PYRIMETHAMINE IN HIV-INFECTED PATIENTS
STEADY-STATE KINETICS OF DAPSONE, MONO-ACETYL-DAPSONE AND PYRIMETHAMINE DURING ANTIPROTOZOAL PROPHYLAXIS IN HIV-INFECTED PATIENTS
POST-ZIDOVUDINE THERAPEUTIC APPROACH
COMBINED THERAPY WITH ZIDOVUDINE PLUS ALPHA INTERFERON 2b R
ZIDOVUDINE PLUS THYMOSTIMULIN
The Short-Term Safety and Laboratory Marker Effect of ZDV+ddI vs ZDV+ddC in Subjects with CD4s OF 50 TO 350/pX. A Randomized Comparative Trial with an Open Arm
LONG TERM FOLLOW-UP OF A DOUBLE BLIND STUDY OF ddI vs CONTINUED AZT AMONG INDIVIDUALS WITH CD4s 200–500/mm3
SHOULD WE EMBRACE NEW DRUGS WITH OPEN ARMS? EXPERIENCE WITHIN THE COMMUNITY BASED, OPEN ARM, RANDOMIZED STUDY OF ZDV/ddl VS ZDV/ddC
EFFICACY AND TOLERANCE OF DDI+ZDV VS. DDC+ZDV IN PATIENTS WITH RAPID PROGRESSION OF HIV INFECTION UNDER TREATMENT WITH ZDV
A COMPARATIVE TRIAL BETWEEN AZT+DDI AND MAINTENANCE OF AZT OR DDI IN HIV INFECTED PATIENTS
SAFETY AND EFFICACY OF DIDANOSINE (ddi) IN 100 HIV POSITIVE PATIENTS
THE VALIDITY OF AN HIV ADAPTATION OF THE MEDICAL OUTCOME SURVEY QUALITY OF LIFE SCALE (MOS-HIV) IN A UK POPULATION
AN AUDIT OF BLOOD TRANSFUSION IN HUMAN IMMUNODEFICIENCY VIRUS POSITIVE PATIENTS
Use of Rh Antibodies in the Treatment of HIV-related, Immun Thrombocytopenic Purpura
EFFICACY OF LONG-TERM TREATMENT WITH LOW-DOSE G-CSF (FILGRASTIM) IN PREVENTING SEVERE NEUTROPENIA IN AIDS PATIENTS
HEMOPOIETIC GROWTH FACTORS (HGF) IN THE MANAGEMENT OF PATIENTS WITH ADVANCED STAGE HIV INFECTION
THE USE OF GRANULOC YTE-COLONY STIMULATING FACTOR (G-CSF) IN HIV SEROPOSITIVE INDIVIDUALS
NITRIC OXIDE METABOLISM IN HIV-1 INFECTION
Treatment of HIV infected patients with pentoxifyllin
HIV-infected patients have circulating cytotoxic T lymphocytes anti-PHA-stimulated normal CD4+ lymphocytes
DYSREGULATION OF ADHESION MOLECULE EXPRESSION IN HIV INFECTION - A POTENTIAL TARGET FOR IMMUNOTHERAPY
IMPACT OF ASSAY REPRODUCIBILITY ON QUANTITATION OF PLASMA HIV RNA
Plasma viremia as a sensitive indicator of antiretroviral therapy
HIV protease inhibitor RO 31–8959
NUCLEOSIDE ANALOGUES SUPPRESS VIRAL EXPLICATION IN PATIENTS WITH HIGH VIRUS LOAD IN VITRO BUT INTERFERE WITH T-CELL BLASTOCRNESIS IN EARLIER STAGES OF HIV-INFECTION
HIGH YIELDS OF CD4+ AND CDS+ T-LYMPHOCYTES CAN BE OBTAINED BY LYMPHAPHERESIS AND EX VIVO PROPAGATION FOB AUTOLOGOUS ADOPTIVE IMMUNOTHERAPY OF HIV-INFECTION
CLINICAL EFFICACY AND TOLERABILITY OF DIDANOSINE (ddl) IN RELATION TO SEVERE IMMUNODEPRESSION
EVALUATION OF TWO FLOW CYTOMETERS AND OF TWO AND THREE COLOR FLUORESCENCE LABELLING
THE EXPRESSION OF CD4 AND CD64 RECEPTORS ON THE SURFACE OF HUMAN SPERMATOZOA AND THEIR RELATIONSHIP TO HIV TRANSMISSION
DOES URINARY NEOFTERIN PREDICT FALLING CD4 LYMPHOCYTE COUNTS?
CIGARETTE SMOKING
EMPIRICAL ANTIBIOTIC THERAPY FOR NEUROSYPHILIS IN HIV-1 INFECTION
EFFICACY COMPARISON OF LONG-TERM AZT AND VIROSTATIC COMBINATION TREATMENT (AZT/DDI-AZT/DDC) IN HIV-1-POSITIVE PATIENTS
INFLUENCE OF DDC TREATMENT ON THE PERIPHERAL NERVOUS SYSTEM (PNS) IN HIV-1-POSITIVE PATIENTS
IS THE OUTCOME OF HIV-1-ASSOCIATED ENCEPHALOPHATHY SIGNIFICANTLY INFLUENCED BY ANTIBETROVIRAL TREATMENT?
PILOT STUDY OF THE EFFICACY OF ATEVTRDINE IN AIDS DEMENTIA COMPLEX (ADC)
MALIGNANT NEUROLEPTIC SYNDROME. 4 CASES IN AN IRISH AIDS POPULATION
MOLECULAR HOMOLOGY BETWEEN VISNA VIRUS ENVELOPE AMD SCORPION VENOM,A LIGAHS OF THE SODIUM CHANNEL
Phase I study of single intravenous and subcutaneous ascending doses of GEM 91 in HIV positive, asymptomatic volunteers
SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW CARBOCYCLIC 2',3'-DIDEHYDRO-2',3'-DIDEOXY AND 3'-DEOXY-2'-FLUORO PYRIMIDINE AND PURINE NUCLEOSIDES
ORAL VALACICLOVIR - INCREASED ACYCLOVIR BIOAVAILABILITY IN DIFFERENT PATIENT POPULATIONS
LITHIUM GAMOLENATE INHIBITS HIV REPLICATION IN CHRONICALLY INFECTED H9 CELLS AND ACUTELY INFECTED PBMC
PHASE-II STUDYOFTHE HIV PROTEASE INHIBITOR (SC-52 151 CO. SEARLE) COMPARED TO ZIDOVUDINE (ZDV) FOR THE DETERMINATION OF PHARMACOKINETICS AND EFFICACY
Negatively charged human serum albumins
NEGATIVELY CHARGED ALBUMINS
LOW SERUM SELENIUM LEVELS IN ADVANCED-STAGE HIV-INFECTED PATIENTS
CHANGES OF THE INTESTINAL FUNCTION AND STRUCTURE IN HIV INFECTED PATIENTS WITH CHRONIC DIARRHEA
ACQUIRED IMMUNODEFICIENCY SYNDROME AND NUTRITIONAL STATUS
Are we getting it right? Nutritional Supplement prescribing for HIV positive individuals at St Mary's Hospital. London UK
THE EFFECT OF THE ANABOLIC STEROID, NANDROLONE DECANOATE, ON LEAN BODY MASS AND QUALITY OF LIFE IN HIV+ MEN - A PRELIMINARY ANALYSIS
ELECTRON MICROSCOPY FOR DIAGNOSIS OF ENTERIC PATHOGENS IN HIV-INFECTED PATIENTS
EVALUATION OF THE EFFICACY AND TOLERABILITY OF A NEW ANTIFUNGAL COMPOUND IN CELL CULTURE AND IN RATS WITH P. CARINII PNEUMONIA
INDICATIONS OF INTRAVENOUS IMMUNOGLOBULINES (IVIG) IN HIV INFECTED PATIENTS
OUTCOME MEASURES AND QUALITY OF CARE FOR HIV AND AIDS
GENETIC CHANGES IN AIDS PATIENTS ON PROLONGED GANCICLOVIR THERAPY
MYCOBACTERIUM KANSASH (MK), ITS PRESENTATION, TREATMENT AND OUTCOME
THE USE OF ATOVAQUONE IN HIV POSITIVE PATIENTS
EVIDENCE FOR AN ASSOCIATION OF RIFABUTIN TREATMENT WITH SEVERE UVEITIS IN HIV-INFECTED PATIENTS
TUBERCULOSIS AND HIV INFECTION
PREVENTION OF RESPIRATORY DISEASE WITHIN A COHORT OF GAY MEN - IMPROVING COMPLIANCE WITH CURRENT GUIDELINES
OPPORTUNISTICS INFECTIONS (O.I.) IN 349 PATIENTS WITH PCP PRIMARY PROPHYLAXIS
DAPSONE AS PROPHYLAXIS FOR DISSEMINATED MYCOBACTERIUM AVIUM COMPLEX INFECTION
INDUCED SPUTUM IN 1993
Typical radiological findings in Cytomegalovirus pneumonia
CEREBRAL TOXOPLASMA GONDII INFECTION AMONG NORWEGIAN AIDS PATIENTS. INDICATION FOR PROPHYLAXIS?
CHANGING PATTERN OF AIDS PRESENTATION AMONG 1000 AIDS CASES IN MILAN
Ganciclovir in CMV gastrointestinal disease - Preliminary data of randomised double-blind study of two dose regimens in acute therapy
AZITHROMYCIN THERAPY OF CRYPTOSPORIDIAL DIARRHEA IN AIDS PATIENTS
TREATMENT OF HIV-ASSOCIATED PULMONARY TUBERCULOSIS WITH RIFABUTIN
The Efficacy of Ondansetron for the Therapy of Metoclopramid (MCP) Resistent Emesis in the Treatment of HIV Infection
PSYCHOSOCIAL DETERMINANTS OF TREATMENT COMPLIANCE IN CMV EYE DISEASE
RETROSPECTIVE ANALYSIS OF PORTACATH USE IN AIDS PATIENTS 1990–94
ECONOMIC EVALUATION OF ORAL AND IV GANCICLOVIR IN THE TREATMENT OF AIDS RELATED CYTOMEGALOVIRUS
INTRAVENOUS (IV) INFUSION IN THE COMMUNITY
THE IMPACT OF A HOSPITAL PHARMACY CO-ORDINATED SYSTEM OF PROVIDING DRUGS TO PATIENTS WITH CMV RETINITIS
DISEASE DUE TO MYCOBACTERIUM TUBERCULOSIS IN HIV INFECTED IN EDINBURGH
UVEITIS AND SERONEGATIVE ARTHROPATHY ASSOCIATED WITH RIFABUTIN TREATMENT OF MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION IN AIDS
SAFETY OF TOTALLY IMPLANTABLE INTRAVENOUS DEVICE-PORTACATH (PAC) IN HIV PATIENTS (p)
DRUG SENSITIVITY AND SYNERGY IN THE TREATMENT OF MAC INFECTION. ARE HIV+ AND HIV- PATIENTS DIFFERENT?
THE TREATMENT OF HERPES SIMPLEX INFECTION WITH “ALPISARINI” IN HIV-INFECTED PATIENTS
Experience with an implantable venous port-system in AIDS-patients
MARKERS OF EARLY OCCURRENCE OF OPPORTUNISTIC INFECTIONS IN PATIENTS WITH PRIMARY HIV INFECTION (PHI)
PROSPECTIVE EVALUATION OF THE CLINICAL EFFICACY OF SHORT-COURSE VS. LONG-TERM FOSCARNET IN THE THERAPY OF AIDS-RELATED CMV GASTROINTESTINAL DISEASE
CLINICAL EFFICACY OF A COMBINATION OF CLARITHROMYCIN AND ETHIONAMIDE IN PATIENTS WITH MAC BACTERAEMIA DUE TO ETHAMBUTOL-RES1STANT STRAINS
MANAGEMENT OF DERMATOLOGICAL PROBLEMS -OTHERS THAN KAPOSI'S SARCOMA - IN HIV INFECTED PATIENTS
Demonstration of a digital picture analysis system for objectivation of ocular fundus changes in CMV-retinitis
BINDING OF GP120 TO CD4 RECEPTORS ON HUMAN TERM TROPHOBLAST CELLS IN CULTURE
CHANGES IN VIRAL LOAD AND RESISTANCE MUTATIONS IN HIV-1 INFECTED CHILDREN TREATED WITH ZIDOVUDINE
HIV-related Non Hodgkin's Lymphoma of the Gastrointestinal Tract
HIV-related Non Hodgkin's Lymphoma
Liposomal Doxorubicin as a Long-Term Treatment for Advanced HI V-Associated Kaposi's Sarcoma
FILGRASTIM (r-metHuG-CSF, Amgen), CEOP AND ANTIRETROVIRAL THERAPY IN HIV- RELATED NON-HODGKINS LYMPHOMA (NHL)
EFFICACY AND TOXICITY OF DOXIL ( STEALTH LIPOSOMAL DOXORUBICIN HCL) IN MODERATE/ SEVERE EPIDEMIC KAPOSI'S SARCOMA
EPIDEMIC KAPOSI'S SARCOMA (EKS)
TACRINE BREAKTHROUGH
Two AIDS patients with visceral leishmaniasis (case reports) more questions than before?
ANTI-CD4IDIOTYPE VACCINATION IN HIV DISEASE*
Intensive Phase II Therapeutie HIV Vaccine Trials Can Be Appropriately Conducted Through Community Networks
Treatment of herpetic lesions in HIV-infected persons in a Palliative Care Unit (PCU)
TREATMENT OF RENAL AND PROSTATIC ASPERGILLOSIS WITH ITRACONAZOL
TREATMENT OF LEUCOPENIA WITH FILGASTRIM (G-CSF) IN HIV INFECTED PATIENTS
HIV ASSOCIATED HEMOPHAGOCYTIC SYNDROME AND CASTLEMANN'S DISEASE
SEVERE HEPATITIS DUE TO CO-INFECTION WITH HIV AND HEPATITIS C VIRUS IN A YOUNG INFANT
DRUG INFORMATION IN HIV DISEASE
A SURVEY OF PATIENTS' ATTITUDES TO ZIDOVUDINE IN THE WAKE OF THE CONCORDE TRIAL
HIV CLINICAL TRIALS
HAS THERE BEEN A ‘CONCORDE’ EFFECT? PATIENT AND PHYSICIAN ATTITUDES TO ANTIVIRAL TREATMENT
COURSE OF HIV- INFECTION AND ANNUAL CD4 LOSS IN GERMAN INJECTING DRUG USERS (IDU) WITH AND WITHOUT METHADONE USE
THE EFFECT OF LOW PH, GENITAL SECRETIONS AND VIRUCIDAL AGENTS AGAINST HIV-1
A PILOT STUDY OF THE SAFETY. TOLERANCE AND RESIDENCE TIME OF DEXTRIN SULPHATE GEL, A NOVEL POTENTIAL INTRAVAGINAL VIRUCIDE
ALPHA INTERFERON FOR HEPATITIS C INFECTION IN HIV SEROPOSITIVE AND SERONEGATIVE HAEMOPHILIC PATIENTS
MULTICENTER AIDS COOPERATION IN GERMANY
THE POST-CONCORDE ERA